EP2492262B1 - Composés hétérocycles fusionnés et activateur du récepteur de la thrombopoïétine - Google Patents

Composés hétérocycles fusionnés et activateur du récepteur de la thrombopoïétine Download PDF

Info

Publication number
EP2492262B1
EP2492262B1 EP10825062.2A EP10825062A EP2492262B1 EP 2492262 B1 EP2492262 B1 EP 2492262B1 EP 10825062 A EP10825062 A EP 10825062A EP 2492262 B1 EP2492262 B1 EP 2492262B1
Authority
EP
European Patent Office
Prior art keywords
group
groups
substituted
methyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP10825062.2A
Other languages
German (de)
English (en)
Other versions
EP2492262A1 (fr
EP2492262A4 (fr
Inventor
Yukihiro Shigeta
Shingo UMEZAWA
Shunsuke Iwamoto
Takanori Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Publication of EP2492262A1 publication Critical patent/EP2492262A1/fr
Publication of EP2492262A4 publication Critical patent/EP2492262A4/fr
Application granted granted Critical
Publication of EP2492262B1 publication Critical patent/EP2492262B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to preventive, therapeutic and improving agents having affinity for and agonistic action on the thrombopoietin receptor for diseases against which activation of the thrombopoietin receptor is effective.
  • it relates to pharmaceutical compositions comprising compounds which increase platelets through stimulation of differentiation and proliferation of hematopoietic stem cells, megakaryocytic progenitor cells and megakaryocytes, compounds for therapeutic angiogenesis that stimulate differentiation and proliferation of vascular endothelial cells and endothelial progenitor cells or compounds with anti-arteriosclerosis action.
  • Thrombopoietin is a cytokine consisting of 332 amino acids that increases platelet production by stimulating differentiation and proliferation of hematopoietic stem cells, megakaryocytic progenitor cells and megakaryocytes mediated by its receptor and therefore is promising as a drug for hematological disorders.
  • Recent reports that it stimulates differentiation and proliferation of vascular endothelial cells and endothelial progenitor cells have raised expectations of therapeutic angiogenesis, anti-arteriosclerosis and prevention of cardiovascular events (for example, non-patent document 1, non-patent document 2 and non-patent document 3).
  • Biologically active substances which have been known so far to regulate platelet production through the thrombopoietin receptor include, in addition to thrombopoietin itself, low molecular weight peptides having affinity for the thrombopoietin receptor (for example, patent document 1, patent document 2, patent document 3 and patent document 4).
  • Thrombopoietin and low molecular weight peptides having affinity for the thrombopoietin receptor are likely to be easily degraded in the gastrointestinal tract and are usually difficult to orally administer.
  • thrombopoietin itself the appearance of anti-thrombopoietin antibodies have been reported.
  • novel low molecular weight compounds which can serve as platelet increasing agents or increasing agents for other blood cells by stimulating differentiation and proliferation of hematopoietic stem cells, megakaryocytic progenitor cells and megakaryocytes, low molecular weight compounds which can be used for therapeutic angiogenesis by stimulating endothelial cells and endothelial progenitor cells or novel compounds which can be used as preventive and therapeutic agents for arteriosclerosis have been demanded.
  • the present inventors conducted extensive research to find low molecular weight compounds having affinity for and agonistic action on the thrombopoietin receptor, and as a result, found that the compounds of the present invention have high affinity and agonistic action which enable them to show potent platelet increasing action by stimulating differentiation and proliferation of megakaryocytic progenitor cells and megakaryocytes.
  • the present invention was accomplished on the basis of this discover.I
  • the present invention provides:
  • n denotes normal
  • i denotes iso
  • s denotes secondary
  • t or “tert” denotes tertiary
  • c denotes cyclo
  • o denotes ortho
  • m denotes meta
  • p denotes para
  • Ph denotes phenyl
  • Py denotes pyridyl
  • Me denotes methyl
  • Et denotes ethyl
  • Pr denotes propyl
  • Bu denotes butyl
  • Boc denotes tertiary-butoxycarbonyl
  • Ms denotes methanesulfonyl
  • Tf denotes trifluoromethanesulfonyl
  • MOM denotes methoxymethyl.
  • the number of substitutable positions on the moiety defines the number of the upper limit of the number of substituents.
  • the substituent may be present on a ring-constituting carbon atom or a ring-constituting nitrogen atom.
  • halogen atom fluorine, chlorine, bromine or iodine may be mentioned.
  • a C 1-3 alkyl group is an alkyl group containing one to three carbon atoms and may be linear, branched or a C 3 cycloalkyl group.
  • a methyl group, an ethyl group, a n-propyl group, an i-propyl group and a c-propyl group may be mentioned.
  • a C 1-6 alkyl group is an alkyl group containing one to six carbon atoms and may be linear, branched or a C 3-6 cycloalkyl group.
  • a C 1-3 haloalkyl group is a C 1-3 alkyl group such as those mentioned above which is substituted with one or more halogen atoms.
  • a chloromethyl group, a trifluoromethyl group, a difluoromethyl group and the like may be mentioned.
  • a C 1-6 alkylene group is a bivalent group obtained by removing a hydrogen atom 15 from the above-mentioned C 1-6 alkyl group and may be a linear, branched or cyclic alkylene containing one to six carbon atoms.
  • a methylene group, an ethylene group, a propylene group, an isopropylene group, a c-propylene group, an ethylpropylene group, a butylene group, an isobutylene group, a c-butylene group, an ethylbutylene group, a pentylene group, a c-pentylene group, a hexylene group or a c-hexylene group may be mentioned.
  • a C 3-10 cycloalkyl group is a cycloalkyl group containing three to ten carbon atoms and may have a fused polycyclic structure, a bridged cyclic structure or a spirocyclic structure.
  • a C 4-7 cyloalkyl group means a cycloalkyl group containing four to seven carbon atoms.
  • a c-butyl group, a c-pentyl group, a c-hexyl group, a c-heptyl group and the like may be mentioned.
  • a C 2-6 alkenyl group means a group obtained by converting arbitrary one, two or three bonds in the above-mentioned C 1-6 alkyl group (other than a methyl group) to double bonds, and may be linear, branched or a C 3-6 cycloalkenyl group.
  • a C 2-6 alykenylene group is a bivalent group obtained by removing a hydrogen atom from the above-mentioned C 2-6 alkenyl group and may be a linear, branched or cyclic alkenylene group.
  • an ethenylene group, a propenylene group, an isopropenylene group, a c-propenylene group, an ethylpropenylene group, a butenylene group, an isobutenylene group, a c-butenylene group, an ethylbutenylene group, a pentenylene group, a c-pentenylene group, a hexenylene group and a c-hexenylene group may be mentioned.
  • a C 3-10 cycloalkenyl group means a group obtained by converting arbitrary one, two or three bonds in the above-mentioned C 3-10 cycloalkyl group to double bonds and may have a fused polycyclic structure, a bridged cyclic structure or a spirocyclic structure.
  • a C 2-6 alkynyl group is an alkynyl group having two to six carbon atoms and may be linear, branched or a C 6 cycloalkynyl group.
  • a C 2-6 alkynylene group is a bivalent group obtained by removing a hydrogen atom from the above-mentioned C 2-6 alkynyl group and may be linear, branched or cyclic.
  • an ethynylene group, a propynylene group, an isopropynylene group, a c-propynylene group, an ethylpropynylene group, a butynylene group, an isobutynylene group, a c-butynylene group, an ethylbutynylene group, a pentynylene group, a c-pentynylene group, a hexynylene group and a c-hexynylene group may be mentioned.
  • a C 1-6 alkoxy group is an alkoxy group having one to six carbon atoms and may be linear, branched or a C 3-6 cycloalkoxy group.
  • a C 1-3 alkoxy group is an alkoxy group having one to three carbon atoms and may be linear, branched or a C 3 cycloalkoxy group.
  • a methoxy group, an ethoxy group, a n-propoxy group, an i-propoxy group, a c-propoxy group and the like may be mentioned.
  • a C 1-3 haloalkoxy group is a C 1-3 alkoxy group such as those mentioned above in which the alkoxy group is substituted with one or more halogen atoms.
  • a chloromethoxy group, a trifluoromethoxy group, a difluoromethoxy group, a monofluoromethoxy group and the like may be mentioned.
  • a C 2-14 aryl group means a C 6-14 aryl group containing no hetero atoms as ring constituting atoms or a C 2-9 aromatic heterocyclic group.
  • a C 6-14 aryl group containing no hetero atoms is an aryl group containing six to fourteen carbon atoms, and as specific examples, a phenyl group, an ⁇ -naphthyl group, a ⁇ -naphthyl group, an ⁇ -biphenylyl group, a m-biphenylyl group, a p-biphenylyl group, a 1-anthryl group, a 2-anthryl group, a 9-anthryl group, a 1-phenanthryl group, a 2-phenanthryl group, a 3-phenanthryl group, a 4-phenanthryl group, a 9-phenanthryl group and the like may be mentioned.
  • a C 2-9 aromatic heterocyclic group means a 5 to 7-membered C 2-6 heteromonocyclic group or a 8 to 10-membered C 5-9 fused heterobicyclic group containing from 1 to 3 oxygen atoms, nitrogen atoms or sulfur atoms singly or in combination, and, if contains one or more nitrogen atoms, may be in the form of an N-oxide.
  • a 8 to 10-membered C 5-9 fused heterobicyclic group may be a 2-benzofuranyl group, a 3-benzofuranyl group, a 4-benzofuranyl group, a 5-benzofuranyl group, a 6-benzofuranyl group, a 7-benzofuranyl group, a 1-isobenzofuranyl group, a 4-isobenzofuranyl group, a 5-isobenzofuranyl group, a 2-benzothienyl group, a 3-benzothienyl group, a 4-benzothienyl group, a 5-benzothienyl group, a 6-benzothienyl group, a 7-benzothienyl group, a 1-isobenzothienyl group, a 4-isobenzothienyl group, a 5-isobenzothienyl group, a 1-indolizinyl group, a 2-indolizinyl group, a 3-indolizinyl
  • a C 4-6 aryl group means an aromatic group constituted by four to six carbon atoms and zero to one hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom (provided that when there are no hetero atoms, the number of carbon atoms is six).
  • a phenyl group, a pyridyl group, a thienyl group, a pyrrolyl group, a furyl group or the like may be mentioned.
  • a C 2-9 heterocyclyl group is a heteromonocyclic or fused heterobicyclic group consisting of at least one atom arbitrarily selected from nitrogen atoms, oxygen atoms and sulfur atoms and two to nine carbon atoms, and carbon atoms constituting the ring may be carbonyl or thiocarbonyl. As specific examples, may be mentioned.
  • a nitrogen-containing heterocyclyl group is a heteromonocyclic or fused heterobicyclic group containing at least one nitrogen atom and two to nine carbon atoms which may further contain at least one atoms arbitrary selected from oxygen atoms and sulfur atoms, and carbon atoms constituting the ring may be carbonyl or thiocarbonyl. As specific examples, may be mentioned.
  • a C 4-5 nitrogen-containing heterocyclyl group means a group having a ring structure consisting of one to two nitrogen or oxygen atoms and four to five carbon atoms and having no unsaturated bonds.
  • a piperazinyl group, a piperidinyl group, a pyrrolidinyl group, a morpholinyl group and the like may be mentioned.
  • it is a group having a ring structure consisting of one to two nitrogen atoms and four to five carbon atoms and having no saturated bonds.
  • a C 3-5 oxygen-containing heterocyclyl group means a group having a ring structure consisting of one to two oxygen atoms and three to five carbon atoms and having no unsaturated bonds.
  • a tetrahydrofuranyl group, a tetrahydro-2H-pyranyl group, a 1,3-dioxolanyl group, a 1,4-dioxanyl group and the like may be mentioned.
  • a mono-C 1-6 alkylamino group is an amino group containing one C 1-6 alkyl group and may be linear, branched or a C 3-6 cycloalkylamino group, and as specific examples, a methylamino group, an ethylamino group, a n-propylamino group, an i-propylamino group, a c-propylamino group, a n-butylamino group, an i-butylamino group, a s-butylamino group, a t-butylamino group, a c-butylamino group, a 1-methyl-c-propylamino group, a 2-methyl-c-propylamino group, a n-pentylamino group, a 1-methyl-n-butylamino group, a 2-methyl-n-butylamino group, a 3-methyl-n-butylamino group, a 1,
  • a di-C 1-6 alkylamino group is an amino group having two C 1-6 alkyl groups and may be symmetric or asymmetric.
  • a symmetric C 1-6 dialkylamino group may be linear, branched or a C 3-6 cycloalkylamino group, and as specific examples, a dimethylamino group, a diethylamino group, a di-n-propylamino group, a di-i-propylamino group, a di-c-propylamino group, a di-n-butylamino group, a di-i-butylamino group, a di-s-butylamino group, a di-t-butylamino group, a di-c-butylamino group, a di-(1-methyl-c-propyl)amino group, a di-(2-methyl-c-propyl)amino group, a di-n-pentylamino group,
  • An asymmetric di-C 1-6 alkylamino group may be linear, branched or a C 3-6 cycloalkylamino group, and as specific examples, a (methyl, ethyl)amino group, a (methyl, n-propyl)amino group, a (methyl, i-propyl)amino group, a (methyl, c-propyl)amino group, a (methyl, n-butyl)amino group, a (methyl, i-butyl)amino group, a (methyl, s-butyl)amino group, a (methyl, t-butyl)amino group, a (methyl, n-pentyl)amino group, a (methyl, c-pentyl)amino group, a (methyl, n-hexyl)amino group, a (methyl, c-hexyl)amino group, a (e
  • a C 1-6 alkylthio group is a thio group having a C 1-6 alkyl group and may be linear, branched or a C 3-6 cycloalkylthio group.
  • a C 1-6 alkylsulfonyl group is a sulfonyl group having a C 1-6 alkyl group and may be linear, branched or a C 3-6 cycloalkylsulfonyl group.
  • a mono-C 1-6 alkylaminocarbonyl group is an aminocarbonyl group having a C 1-6 alkyl group and may be linear, branched or a C 3-6 cycloalkylaminocarbonyl group.
  • a di-C 1-6 alkylaminocarbonyl group is an aminocarbonyl group having two C 1-6 alkyl groups and may be symmetric or asymmetric.
  • a symmetric C 1-6 dialkylaminocarbonyl group may be linear, branched or a C 3-6 cycloalkylaminocarbonyl group, and as specific examples, a dimethylaminocarbonyl group, a diethylaminocarbonyl group, a di-n-propylaminocarbonyl group, a di-i-propylaminocarbonyl group, a di-c-propylaminocarbonyl group, a di-n-butylaminocarbonyl group, a di-i-butylaminocarbonyl group, a di-s-butylaminocarbonyl group, a di-t-butylaminocarbonyl group, a di-c-butylaminocarbonyl group, a di-(1-methyl-c-prop
  • An asymmetric di-C 1-6 alkylaminocarbonyl group may be linear, branched or a C 3-6 cycloalkylaminocarbonyl group.
  • a C 1-6 alkylcarbonyl group is a carbonyl group having a C 1-6 alkyl group and may be linear, branched or a C 3-6 cycloalkylcarbonyl group.
  • a C 1-6 alkloxycarbonyl group is a carbonyl group having a C 1-6 alkoxy group and may be linear, branched or a C 3-6 cycloalkoxycarbonyl group.
  • a C 1-6 alkylcarbonylamino group is an amino group having a C 1-6 alkylcarbonyl group and may be linear or branched or may contain a C 3-6 cycloalkylcarbonylamino group.
  • a C 2-14 aryl group fused to a C 2-9 heterocyclyl group means a structure consisting of a C 2-9 heterocyclyl group and a C 2-14 aryl group fused together.
  • the C 2-9 heterocyclyl group is restricted so as to exclude C 2-9 heterocyclyl groups which aromatize upon fusion to the aryl group, such as a dihydropyrrolyl group, which forms an indole ring upon fusion to a phenyl group.
  • a phenyl group fused to a C 2-9 heterocyclyl group means a structure consisting of the above-mentioned C 2-9 heterocyclyl group and a phenyl group fused together, sharing two carbon atoms.
  • the C 2-9 heterocyclyl group is restricted so as to exclude C 2-9 heterocyclyl groups which aromatize upon fusion to the phenyl group, such as a dihydropyrrolyl group, which forms an indole ring upon fusion to a phenyl group.
  • a C 2-14 aryl group fused to a C 3-10 cycloalkyl group means a structure consisting of a C 3-10 cycloalkyl group and the above-mentioned C 2-14 aryl group fused together, and as specific example, the following structures may be mentioned.
  • a phenyl group fused to a C 3-10 cycloalkyl group means a structure consisting of a C 3-10 cycloalkyl group and a phenyl group fused together, sharing two carbon atoms, and as specific example, the following structures may be mentioned.
  • a phenyl group fused to a C 4-7 cycloalkyl group means a structure consisting of a C 4-7 cycloalkyl group and a phenyl group fused together, sharing two carbon atoms, and as specific example, the following structures may be mentioned.
  • a phenyl group fused to a C 3-5 oxygen-containing heterocyclyl group means a structure consisting of the above-mentioned C 3-5 oxygen-containing heterocyclyl group and a phenyl group fused together, sharing two carbon atoms, and the C 3-5 oxygen-containing heterocyclyl group constituting the ring is a non-aromatic heterocyclic group.
  • the following structures may be mentioned.
  • a C 2-14 aryl group fused to a C 3-10 cycloalkenyl group means a structure consisting of the above-mentioned C 3-10 cycloalkenyl group and the above-mentioned C 2-14 aryl group fused together, and as specific example, the following structures may be mentioned.
  • the C 3-10 cycloalkenyl group is restricted to exclude C 3-10 cycloalkenyl groups which aromatize upon fusion to the C 2-14 aryl group, such as a c-hexa-1,3-dienyl group, which forms a nathphalene ring upon fusion to a phenyl group.
  • a preferred embodiment of the substituents A and B is such that A is a nitrogen atom or CR 4 (wherein R 4 is a hydrogen atom, a halogen atom or a C 1-6 alkyl group (the C 1-6 alkyl group is unsubstituted or substituted with one or more halogen atoms)), and B is NR 5 (wherein R 5 is a C 1-6 alkyl group (the alkyl group is unsubstituted or substituted with one or more halogen atoms)) or a sulfur atom.
  • a more preferred embodiment of the substituents A and B is such that A is a nitrogen atom, B is NR 5 (wherein R 5 is a C 1-6 alkyl group (the C 1-6 alkyl group is unsubstituted or substituted with one or more halogen atoms)).
  • A is CR 4 (wherein R 4 is a hydrogen atom, a halogen atom or a C 1-6 alkyl group (the alkyl group is unsubstituted or substituted with one or more halogen atoms)), and B is a sulfur atom.
  • a more particularly preferred embodiment of the substituents A and B is such that A is a nitrogen atom, and B is NR 5 (wherein R 5 is a C 1-3 alkyl group).
  • A is CR 4 (wherein R 4 is a hydrogen atom), and B is a sulfur atom.
  • a preferred embodiment of the substituent R 1 is a C 2-14 aryl group fused to a C 3-10 cycloalkenyl group (the C 2-14 aryl group fused to a C 3-10 cycloalkenyl group is unsubstituted or substituted with one or more substituents selected from the group consisting of carboxy groups, carbamoyl groups, sulfamoyl groups, phosphono groups, sulfo groups, tetrazolyl groups, formyl groups, hydroxy groups, nitro groups, cyano groups, halogen atoms, C 1-6 alkyl groups, C 1-3 haloalkyl groups, C 1-3 haloalkoxy groups, C 2-6 alkenyl groups, C 2-9 heterocyclyl groups, mono-C 1-6 alkylaminocarbonyl groups, di-C 1-6 alkylaminocarbonyl groups and C 1-6 alkylsulfonyl groups).
  • substituent R 1 is a phenyl group fused to a C 3-10 cycloalkyl group (the phenyl group fused to a C 3-10 cycloalkenyl group is unsubstituted or substituted with one or more substituents selected from the group consisting of carboxy groups, carbamoyl groups, sulfamoyl groups, phosphono groups, sulfo groups, tetrazolyl groups, formyl groups, hydroxy groups, nitro groups, cyano groups, halogen atoms, C 1-6 alkyl groups, C 1-3 haloalkyl groups, C 1-3 haloalkoxy groups, C 2-6 alkenyl groups, C 2-9 heterocyclyl groups, mono-C 1-6 alkylaminocarbonyl groups, di-C 1-6 alkylaminocarbonyl groups and C 1-6 alkylsulfonyl groups).
  • substituents selected from the group consisting of carboxy groups, carbamoy
  • substituent R 1 is a phenyl group fused to a C 2-9 heterocyclyl group (the phenyl group fused to a C 2-9 heterocyclyl group is unsubstituted or substituted with one or more substituents selected from the group consisting of carboxy groups, carbamoyl groups, sulfamoyl groups, phosphono groups, sulfo groups, tetrazolyl groups, formyl groups, hydroxy groups, nitro groups, cyano groups, halogen atoms, C 1-6 alkyl groups, C 1-3 haloalkyl groups, C 1-3 haloalkoxy groups, C 2-6 alkenyl groups, C 2-9 heterocyclyl groups, mono-C 1-6 alkylaminocarbonyl groups, di-C 1-6 alkylaminocarbonyl groups and C 1-6 alkylsulfonyl groups).
  • substituents selected from the group consisting of carboxy groups, carbamoyl groups, s
  • a more preferred embodiment of the substituent R 1 is a phenyl group fused to a C 2-9 heterocyclyl group.
  • R 1 Another more preferred embodiment of the substituent R 1 is a phenyl group fused to a C 3-10 cycloalkyl group.
  • a particularly preferred embodiment of the substituent R 1 is a phenyl group fused to a C 3-5 oxygen-containing heterocyclyl group.
  • R 1 is a phenyl group fused to a C 4-7 cycloalkyl group.
  • R 1 Another particularly preferred embodiment of the substituent R 1 is any of the following structures.
  • R 1 Another particularly preferred embodiment of the substituent R 1 is any of the following structures.
  • R 1 Another particularly preferred embodiment of the substituent R 1 is any of the following structures.
  • a more particularly preferred embodiment of the substituent R 1 is an indanyl group.
  • R 1 is a tetrahydronaphthyl group.
  • R 1 is a 2,3-dihydrobenzofuranyl group.
  • Preferred embodiments of the substituents L 1 and L 2 are single bonds.
  • a preferred embodiment of X is OH.
  • a preferred embodiment of the substituent R 2 is preferably a hydrogen atom, a C 1-6 alkyl group or a C 2-6 alkenyl group (the C 1-6 alkyl group and the C 2-6 alkenyl group are unsubstituted or substituted with one or more halogen atoms).
  • R 2 is a hydrogen atom, a C 1-6 alkyl group (the C 1-6 alkyl group is unsubstituted or substituted with one or more halogen atoms).
  • a more particularly preferred embodiment of the substituent R 2 is a methyl group.
  • L 3 is NR 8 (wherein R 8 is a hydrogen atom or a C 1-6 alkyl group (the C 1-6 alkyl group is unsubstituted or substituted with one or more halogen atoms)).
  • a more preferred embodiment of L 3 is NH.
  • L 4 is a single bond or NR 8 (wherein R 8 is a hydrogen atom or a C 1-6 alkyl group (the C 1-6 alkyl group is unsubstituted or substituted with one or more halogen atoms)).
  • a more preferred embodiment of L 4 is a single bond or NH.
  • a preferred embodiment of Y is an oxygen atom or a sulfur atom.
  • R 3 is a C 4-6 aryl group substituted with a carboxy group or a C 1-6 alkoxycarbonyl group.
  • R 3 is aC 4-6 aryl group substituted with a carboxy group or a C 1-6 alkoxycarbonyl group and with a substituent selected from the group consisting of a halogen atom, a cyano group and a nitro group.
  • R 3 is a C 4-6 aryl group substituted with a CONR 14 R 15 (wherein R 14 is a hydrogen atom or a C 1-6 alkyl group, and R 15 is a C 1-6 alkyl group (the C 1-6 alkyl group is unsubstituted or substituted with one or more C 4-6 aryl groups), or NR 14 R 15 , as a whole, means a C 4-5 nitrogen-containing heterocyclyl group (the C 4-5 nitrogen-containing heterocyclyl group is unsubstituted or substituted with one or more carboxy groups, one or more carbamoyl groups, one or more sulfamoyl groups, one or more phosphono groups, one or more sulfo groups, one or more tetrazolyl groups, one or more formyl groups, one or more nitro groups, one or more cyano groups, one or more halogen atoms, one or more hydroxy groups, one or more C 1-6 alkyl groups,
  • R 3 is a C 4-5 nitrogen-containing heterocyclyl group substituted with a subsituent selected from the group consisting of a carboxy group, a C 1-6 alkoxycarbonyl group, a C 1-6 alkylcarbonyl group, a mono-C 1-6 alkylaminocarbonyl group and a di-C 1-6 alkylaminocarbonyl group.
  • R 3 is a C 4-6 aryl group (the C 4-6 aryl group is substituted with a tetrazolyl group).
  • R 3 is a C 4-6 aryl group (the C 4-6 aryl group is substituted with a mono-C 1-6 alkylaminocarbonyl group (the mono-C 1-6 alkylaminocarbonyl group is substituted with a C 4-6 aryl group (the C 4-6 aryl group is substituted with a mono-C 1-6 alkylaminocarbonyl group (the mono-C 1-6 alkylaminocarbonyl group is substituted with a hydroxy group))).
  • R 3 is a phenyl group substituted with a carboxy group or a C 1-6 alkoxycarbonyl group and with a substituent selected from a halogen atom, a cyano group and a nitro group.
  • R 3 Another more preffered embodiment of R 3 is a C 4-6 aryl group substituted with a carboxy group or a C 1-6 alkoxycarbonyl group.
  • R 3 is a C 4-6 aryl group substituted with a CONR 14 R 15 (wherein R 14 is a hydrogen atom or a C 1-3 alkyl group, and R 15 is a C 1-3 alkyl group (the C 1-3 alkyl group is unsubstituted or substituted with one or more C 4-6 aryl groups), or NR 14 R 15 , as a whole, means a C 4-5 nitrogen-containing heterocyclyl group).
  • R 3 is a C 4-5 nitrogen-containing heterocyclyl group substituted with a carboxy group or a C 1-6 alkoxycarbonyl group.
  • R 3 is a phenyl group substituted with a carboxy group.
  • R 3 is a phenyl group substituted with a carboxy group and with a substituent selected from the group consisting of a nitro group and a halogen atom.
  • R 3 is a thienyl group substituted with a carboxy group.
  • R 3 is a thienyl group substituted with a CONR 14 R 15 (wherein R 14 is a hydrogen atom or a C 1-3 alkyl group, and R 15 is a C 1-3 alkyl group (the C 1-3 alkyl group is unsubstituted or substituted with one or more C 4-6 aryl groups)).
  • R 14 is a hydrogen atom or a C 1-3 alkyl group
  • R 15 is a C 1-3 alkyl group (the C 1-3 alkyl group is unsubstituted or substituted with one or more C 4-6 aryl groups)).
  • R 3 is a thienyl group substituted with a CONR 14 R 15 (wherein NR 14 R 15 , as a whole, means a C 4-5 nitrogen-containing heterocyclyl group).
  • R 3 is a thienyl group substituted with a substituent selected from the group consisting of a di-C 1-6 alkylaminocarbonyl group, a mono-C 1-6 alkylaminocarbonyl group (the mono-C 1-6 alkylaminocarbonyl group is substituted with a pyridyl group) and a pyrrolidine-1-carbonyl group.
  • R 3 is a piperidinyl group or a piperazinyl group substituted with a carboxy group.
  • R 3 is a phenyl group substituted with a tetrazolyl group.
  • R 3 is a thienyl group (the thienyl group is substituted with a mono-C 1-6 alkylaminocaronyl group (the mono-C 1-6 alkylaminocaronyl group is substituted with a phenyl group (the phenyl group is substituted with a mono-C 1-6 alkylaminocaronyl group (the mono-C 1-6 alkylaminocaronyl group is substituted with a hydroxy group))).
  • R 1 is a phenyl group fused to a C 3-10 cycloalkyl group or a phenyl group fused to a C 2-9 heterocyclyl group (the phenyl group fused to a C 3-10 cycloalkyl group and the phenyl group fused to a C 2-9 heterocyclyl group are unsubstituted or substituted with one or more carboxy groups, one or more carbamoyl groups, one or more sulfamoyl groups, one or more phosphono groups, one or more sulfo groups, one or more tetrazolyl groups, one or more formyl groups, one or more nitro groups, one or more cyano groups, one or more halogen atoms, one or more C 1-6 alkyl groups, one or more C 2-6 alkenyl groups, one or more C 2-9 heterocyclyl groups, one or more mono-C 1-6 alkyla
  • the compounds according to (6), whrein R 1 is any of the following structures, tautomers, prodrugs or pharmaceutically acceptable salts of the compounds or solvates thereof.
  • the compounds according to (6), whrein R 1 is any of the following structures, tautomers, prodrugs or pharmaceutically acceptable salts of the compounds or solvates thereof.
  • the compounds according to (6), whrein R 1 is an indanyl group, tautomers, prodrugs or pharmaceutically acceptable salts of the compounds or solvates thereof.
  • the compounds according to (6), whrein R 1 is a tetrahydronaphthyl group , tautomers, prodrugs or pharmaceutically acceptable salts of the compounds or solvates thereof.
  • R 1 is a 2,3-dihydrobenzofuranyl group, tautomers, prodrugs or pharmaceutically acceptable salts of the compounds or solvates thereof.
  • R 2 is a hydrogen atom or a C 1-6 alkyl group (the C 1-6 alkyl group is unsubstituted or substituted with one or more halogen atoms), tautomers, prodrugs or pharmaceutically acceptable salts of the compounds or solvates thereof.
  • R 2 is a hydrogen atom or a methyl group, tautomers, prodrugs or pharmaceutically acceptable salts of the compounds or solvates thereof.
  • R 3 is a thienyl group substituted with a di-C 1-6 alkylaminocarbonyl group, a mono-C 1-6 alkylaminocarbonyl group (the mono-C 1-6 alkylaminocarbonyl group is substituted with a pyridyl group) or a pyrrolidine-1-carbonyl group, tautomers, prodrugs or pharmaceutically acceptable salts of the compounds or solvates thereof.
  • L 4 is NR 8 (wherein R 8 is a hydrogen atom or a C 1-6 alkyl group (the C 1-6 alkyl group is unsubstituted or substituted with one or more halogen atoms)), Y is a sulfur atom, and R 3 is a C 4-6 aryl group substituted with a carboxy group or a C 1-6 alkoxycarbonyl group, tautomers, prodrugs or pharmaceutically acceptable salts of the compounds or solvates thereof.
  • Thrombopoietin receptor activators containing the compounds according to (1) to (54), tautomers, prodrugs or pharmaceutically acceptable salts of the compounds or solvates thereof, as an active ingredient.
  • Preventive, therapeutic and improving agents for diseases against which activation of the thrombopoietin receptor is effective which contain the thrombopoietin receptor activators according to (55), as an active ingredient.
  • Platelet increasing agents containing the thrombopoietin receptor activators according to (55), as an active ingredient.
  • the compounds of the present invention represented by the formula (I) may be present in the form of tautomers or geometrical isomers which undergo endocyclic or exocyclic isomerization, mixtures of tautomers or geometric isomers or mixtures of thereof.
  • the compounds of the present invention may be in the form of resolved optical isomers or in the form of mixtures containing them in certain ratios.
  • the compounds of the present invention can be in the form of diastereomers dues to optical isomerism about them.
  • the compounds of the present invention may be in the form of a mixture of all these isomers in certain ratios.
  • diastereomer can be separated by techniques known well to those skilled in the art such as fractional crystallization, and optical isomers can be obtained by techniques well known in the field of organic chemistry for this purpose.
  • the compounds of the present invention represented by the formula (I) or pharmaceutically acceptable salts thereof may be in the form of arbitrary crystals or arbitrary hydrates, depending on the production conditions.
  • the present invention covers these crystals, hydrates and mixtures. They may be in the form of solvates with organic solvents such as acetone, ethanol and tetrahydrofuran, and the present invention covers any of these forms.
  • the compounds of the present invention represented by the formula (I) may be converted to pharmaceutically acceptable salts or may be liberated from the resulting salts, if necessary.
  • the pharmaceutically acceptable salts of the present invention may be, for example, salts with alkali metals (such as lithium, sodium and potassium), alkaline earth metals (such as magnesium and calcium), ammonium, organic bases and amino acids. They may be salts with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid and sulfuric acid) and organic acids (such as acetic acid, citric acid, maleic acid, fumaric acid, tartaric acid, benzenesulfonic acid, methanesulfonic acid and p-toluenesulfonic acid).
  • the compounds which serve as prodrugs are derivatives of the present invention having chemically or metabolically degradable groups which give pharmacologically active compounds of the present invention upon solvolysis or under physiological conditions in vivo. Methods for selecting or producing appropriate prodrugs are disclosed, for example, in Design of Prodrugs (Elsevier, Amsterdam 1985 ).
  • acyloxy derivatives obtained by reacting the compound with appropriate acyl halides or appropriate acid anhydrides may, for example, be mentioned as prodrugs.
  • Acyloxys particularly preferred as prodrugs include -OCOC 2 H 5 , -OCO(t-Bu), -OCOC 15 H 31 , -OCO(m-CO 2 Na-Ph), -OCOCH 2 CH 2 CO 2 Na, -OCOCH(NH 2 )CH 3 , -OCOCH 2 N(CH 3 ) 2 and the like.
  • amide derivatives obtained by reacting the compound having an amino group with appropriate acid halides or appropriate mixed acid anhydrides may, for example, be mentioned as prodrugs.
  • Amides particularly preferred as prodrugs include -NHCO(CH 2 ) 20 OCH 3 , -NHCOCH(NH 2 )CH 3 and the like.
  • the preventive, therapeutic and improving agents for diseases against which activation of the thrombopoietin receptor is effective which contain the thrombopoietin receptor activators of the present invention, as an active ingredient may usually be administered as oral medicines such as tablets, capsules, powder, granules, pills and syrup, as rectal medicines, percutaneous medicines or injections.
  • the agents of the present invention may be administered as a single therapeutic agent or as a mixture with other therapeutic agents. Though they may be administered as they are, they are usually administered in the form of medical compositions. These pharmaceutical preparations can be obtained by adding pharmacologically and pharmaceutically acceptable additives by conventional methods.
  • Oral liquid preparations may be in the form of aqueous or oily suspensions, solutions, emulsions, syrups or elixirs or may be supplied as dry syrups to be mixed with water or other appropriate solvents before use.
  • Such liquid preparations may contain ordinary additives such as suspending agents, perfumes, diluents and emulsifiers. In the case of rectal administration, they may be administered as suppositories.
  • Suppositories may use an appropriate substance such as cacao butter, laurin tallow, Macrogol, glycerogelatin, Witepsol, sodium stearate and mixtures thereof as the base and may, if necessary, contain an emulsifier, a suspending agent, a preservative and the like.
  • pharmaceutical ingredients such as distilled water for injection, physiological saline, 5% glucose solution, propylene glycol and other solvents or solubilizing agents, a pH regulator, an isotonizing agent and a stabilizer may be used to form aqueous dosage forms or dosage forms which need dissolution before use.
  • the dose of the agents of the present invention for administration to human is usually about from 0.1 to 1000 mg/human/day in the case of oral drugs or rectal administration and about from 0.05 mg to 500 mg/human/day in the case of injections, though it depends on the age and conditions of the patient.
  • the above-mentioned ranges are mere examples, and the dose should be determined from the conditions of the patient.
  • the present invention is used when the use of compounds which have thrombopoietin receptor affinity and act as thrombopoietin receptor agonists are expected to improve pathological conditions.
  • hematological disorders accompanied by abnormal platelet count may be mentioned.
  • it is effective for therapy or prevention of human and mammalian diseases caused by abnormal megakaryopoiesis, especially those accompanied by thrombocytopenia.
  • diseases include thrombocytopenia accompanying chemotherapy or radiotherapy of cancer, thrombocytopenia accompanying antiviral therapy for diseases such as hepatitis C, thrombocytopenia caused by bone marrow transplantation, surgery and serious infections, or gastrointestinal bleeding, but such diseases are not restricted to those mentioned.
  • Typical thrombocytopenias such as aplastic anemia, idiopathic thrombocytopenic purpura, myelodysplastic syndrome, hepatic disease, HIV infection and thrombopoietin deficiency are also targets of the agents of the present invention.
  • the present invention may be used as a peripheral stem cell mobilizer, a megakaryoblastic or megakaryocytic leukemia cell differentiation inducer and a platelet increasing agent for platelet donors.
  • potential applications include therapeutic angiogenesis based on differentiation and proliferation of vascular endothelial cells and endothelial progenitor cells, prevention and therapy of arteriosclerosis, myocardial infarction, unstable angina, peripheral artery occlusive disease, but there is no restriction.
  • the compounds of the present invention can be synthesized by the processes mentioned later, but the production of the compounds of the present invention is not restricted to these general examples.
  • the compounds of the present invention can usually be purified by column chromatography, thin layer chromatography, high performance liquid chromatography (HPLC) or high performance liquid chromatography-mass spectrometry (LC-MS) and, if necessary, they may be obtained with high purity by recrystallization or washing with solvents.
  • HPLC high performance liquid chromatography
  • LC-MS high performance liquid chromatography-mass spectrometry
  • alkali metal salts such as sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, potassium hydroxide, sodium hydroxide, sodium hydride, lithium hydride, sodium amide, t-butoxypotassium, t-butoxysodium, n-butyllithium, lithium diisopropylamide and amines such as pyridine, triethylamine, N,N-diisopropylethylamine, pyrrolidine and N-methylpiperidine, silane reagents such as hexamethyldisilazane, sodium acetate and potassium acetate may be mentioned.
  • any solvents that are stable and inert under the reaction conditions and do not hinder the reactions may be used without any particular restrictions, and sulfoxide solvents represented by dimethyl sulfoxide, amide solvents represented by dimethylformamide or dimethylacetamide, ether solvents represented by diethyl ether, dimethoxyethane, tetrahydrofuran, 1,4-dioxane or cyclopenthyl methyl ether, halogenated solvents represented by dichloromethane, chloroform or 1,2-dichloroethane, nitrile solvents represented by acetonitrile or propionitrile, aromatic hydrocarbon solvents represented by benzene or toluene, hydrocarbon solvents represented by hexane or heptane, ester solvents represented by ethyl acetate, alcohol solvents represented by methanol, ethanol, 1-propanol, 2-propanol or ethylene glycol
  • the reaction temperature is chosen appropriately within the range of from -78°C to the boiling point of the solvent used for the reaction, and the production of the compounds of the present invention may be carried out at ordinary pressure or under pressure or with microwave irradiation.
  • precursors are defined as compounds which can be converted to the desired product, if necessary, through hydrolysis, deprotection, reduction, oxidation, alkylation or the like and include compounds protected with chemically acceptable protective groups. Protection and deprotection may be carried out by generally known protection and deprotection reactions ( Protective Groups in Organic Synthesis, Fourth edition, T. W. Greene, John Wiley & Sons Inc. (2006 )).
  • the compounds having NR 8 as L 3 or its precursor can be obtained from the following intermediate (1) or (2) by a reaction with the intermediate (3) or (4) by referring to WO2004108683 , WO2006062240 or WO2007010954 .
  • intermediate (1) an intermediate represented by the formula (1).
  • intermediates (1), (2), (3) and (4) can be obtained as commercial reagents or by referring to the WO2004108683 , WO2006062240 , WO2007010954 or WO2009107799 .
  • those having a single bond as L 1 or their precursors can be obtained by reacting a compound (5) with an organic metal compound represented by the formula (6) such as an organic boronic acid, an organic boronate, an organic tin compound or an organic magnesium compound in a solvent with heating, if necessary in the presence of a transition metal catalyst such as tetrakistriphenylphosphinopalladium or (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium and/or a base such as potassium carbonate, triethylamine or sodium carbonate, if necessary with heating and stirring (for example, by referring to Sen-i Kinzoku ga Maneku Yuki Gosei, Jiro Tsuji, 1997, KAGAKUDOJIN , and Cross-Coupling Reactions, A Practical Guide, Series: Topics in Current Chemistry, Vol. 219. Miyaura Norio, Springer ).
  • an organic metal compound represented by the formula (6)
  • Intermediates (1) can also be obtained by referring to J. Chem. Soc., Chem. Commun., 22, 1643 (1992).
  • intermediates (1) wherein A is a carbon atom, B is a sulfur atom, X is a hydroxy group, and L 1 and L 2 are single bonds which are referred to as intermediates (14), can be synthesized as shown below through intermediates (7), (8), (9), (10), (11), (12) and (13).
  • a 2-thioacetate intermediate (7) as the starting material to an intermediate (8) in a solvent by using acrylonitrile and a base such as sodium methoxide, if necessary with heating and stirring, then convert the intermediate (8) to an intermediate (9) by using an alkylating agent such as dimethyl sulfate or an alkyl halide and, if necessary, a base, if necessary with heating and stirring, and convert the intermediate (9) to an intermediate (10) by using an oxidizing agent such as sulfuryl chloride or hydrogen peroxide, if necessary with heating and stirring.
  • an alkylating agent such as dimethyl sulfate or an alkyl halide
  • a base if necessary with heating and stirring
  • an oxidizing agent such as sulfuryl chloride or hydrogen peroxide
  • compositions of the eluents used in silica gel column chromatography for purification were expressed by volume ratio.
  • the aqueous layer was extracted with 100 ml of chloroform once, and the extract was combined with the previously chloroform extract, washed with 150ml of saturated aqueous sodium chloride twice, dried over anhydrous sodium sulfate and concentrated under reduced pressure.
  • the ethyl acetate layer was neutralized and washed with saturated aqueous sodium hydrogen carbonate, dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
  • the residue was purified by silica gel column chromatography (eluent: n-hexane) to isolate 5.11 g of an oil (yield: 51.9%).
  • the oil turned out to be a mixture of about 70 to 80% of the 5-bromide and about 30 to 20% of the 4-bromide upon 1 H-NMR analysis.
  • reaction solution 60 ml of 47% aqueous hydrobromic acid was mixed with 8.4 g of copper(II) bromide at room temperature with stirring. To the resulting solution, the diazonium salt solution was added dropwise, and after the dropwise addition, the resulting solution was stirred at room temperature for 1 hour and then stirred at 45°C to 50°C for 30 minutes with heating. The reaction solution was further stirred at 60°C to 70°C for 1 hour to complete the reaction. After the completion of the reaction, the reaction solution was extracted by adding 200 ml of ethyl acetate and 300 ml of water.
  • Synthesis was carried out in the same manner as in Synthetic Example 1 by using 24.4 mg (0.0895 mmol) of 1-[4-hydroxy-5-(5,6,7,8-tetrahydronaphthalen-2-yl)thiophen-3-yl]ethanone and 32.6 mg (0.0900 mmol) of 5-(hydrazinecarbonyl)-N-[4-(2-hydroxyethylcarbamoyl)benzyl]thiophene-2-carboxamide to obtain the desired product (35.8 mg, yield 65%).
  • the responses of thrombopoietin receptor to the compounds of Synthetic Examples of the present invention were assayed using a human leukemic cell line, UT7/EPO-mpl.
  • UT7/EPO-mpl is a stable transformed cell line obtained by introducing into human leukemic cell line UT7/EPO a vector that induces expression of human thrombopoietin receptor (c-mpl) under control of cytomegalovirus immediate-early promoter by the method of Takatoku et al. (J. Biol. Chem., 272:7259-7263 (1997 )). Proliferation of this cell line is stimulated by TPO, while its mother cell line UT7/EPO exhibits no response to TPO.
  • IMDM Invitrogen
  • fetal bovine serum Thermo Electron or BioWest
  • the subcultured cells described above were washed twice with PBS and suspended in IMDM containing 10% fetal bovine serum at a cell density of 6 x 10 4 cells/ml.
  • the cell suspension was transferred to a 96-well tissue culture plate (CORNING) in 100- ⁇ l aliquots.
  • CORNING tissue culture plate
  • either thrombopoietin (Pepro Tech EC) or the compound of Synthetic Examples dissolved in dimethyl sulfoxide were diluted 83-fold with IMDM containing 10% fetal bovine serum and added to the aforementioned cell suspension in 20- ⁇ l aliquots.
  • the cell suspension was incubated in a CO 2 incubator (5% CO 2 , 37°C) for 4 days.
  • biokinetics of the compounds of the present invention as a drug can be assayed in accordance with Assay Example 2 in WO2007/010954 .
  • the compounds of the present invention show good biokinetics as a drug.
  • the action of the compounds of the present invention on the proliferation, differentiation and maturation of megakaryocyte cells can be measured by the megakaryocyte colony assay using human bone marrow cells in accordance with Assay Example 3 in WO2007/010954 .
  • the compounds of the present invention have excellent megakaryocyte colony stimulating activity and increase platelets through the activity.
  • the activities of the compounds of the Synthetic Examples on the nuclear ploidy of megakaryocytes from human hematopoietic progenitor cells and/or platelet production from megakarycytes differentiated from human hematopoietic progenitor cells can be evaluated in accordance with Yamane, Nakamura et al. (Blood, 112:542-550 (2008 )).
  • the compounds of the present invention show good megakaryocyte maturation activity and/or platelet increasing activity in an assay of maturity of megakaryocytes from human hetatopoietic progenitor cells based on nuclear ploidy of megakaryocytes and/or an assay of platelet production from megakaryocytes.
  • a granule preparation containing the following ingredients is prepared.
  • Ingredients Compound represented by the formula (I) 10 mg Lactose 700 mg Corn Starch 274 mg HPC-L 16 mg 1000 mg
  • a compound represented by the formula (I) and lactose are sifted through a 60-mesh sieve.
  • Corn starch is sifted though a 120-mesh sieve. They are mixed in a V-type blender. The powder mixture is kneaded with a low-viscosity hydroxypropylcellulose (HPC-L) aqueous solution, granulated (extrusion granulation, die size 0.5-1 mm) and dried. The resulting dry granules are sifted through a shaking sieve (12/60 mesh) to obtain a granule preparation.
  • HPC-L low-viscosity hydroxypropylcellulose
  • a powder preparation for capsulation containing the following ingredients is prepared.
  • Ingredients Compound represented by the formula (I) 10 mg Lactose 79 mg Corn Starch 10 mg Magnesium Stearate 1 mg 100 mg
  • a compound represented by the formula (I) and lactose are sifted through a 60-mesh sieve.
  • Corn starch is sifted though a 120-mesh sieve. They are mixed with magnesium stearate in a V-type blender. The 10% powder is put in hard gelatin capsules No. 5, 100 mg each.
  • a granule preparation for capsulation containing the following ingredients is prepared.
  • Ingredients Compound represented by the formula (I) 15 mg Lactose 90 mg Corn Starch 42 mg HPC-L 3 mg 150 mg
  • a compound represented by the formula (I) and lactose are sifted through a 60-mesh sieve.
  • Corn starch is sifted though a 120-mesh sieve. They are mixed in a V-type blender. The powder mixture is kneaded with a low-viscosity hydroxypropylcellulose (HPC-L) aqueous solution, granulated and dried. The resulting dry granules are sifted through a shaking sieve (12/60 mesh). The granules are put in hard capsules No. 4, 150 mg each.
  • HPC-L low-viscosity hydroxypropylcellulose
  • a tablet preparation containing the following ingredients is prepared.
  • Ingredients Compound represented by the formula (I) 10 mg Lactose 90 mg Microcrystalline cellulose 30 mg Magnesium Stearate 5 mg CMC-Na 15 mg 150 mg
  • a compound represented by the formula (I), lactose, microcrystalline cellulose and CMC-Na (carboxymethylcellulose sodium salt) are sifted through a 60-mesh sieve and mixed.
  • the powder mixture is mixed with magnesium stearate to give a bulk powder mixture.
  • the powder mixture is compressed directly into 150 mg tablets.
  • An intravenous preparation is prepared as follows.
  • Compound represented by the formula (I) 100 mg Saturated Fatty Acid Glyceride 1000 mL
  • Solutions having the above-mentioned composition are usually administered to a patient intravenously at a rate of 1 mL per 1 minute.
  • the fused heterocyclic compounds of the present invention servelate differentiation and proliferation of hematopoietic stem cells, megakaryocytic progenitor cells and megakaryocytes, increase platelets, stimulate differentiation and proliferation of vascular endothelial cells and ehdothelical progenitor cells, have anti-arteriosclerosis action, are effective for therapeutic angeogenesis and useful as an ingredient of preventive, therapeutic and improving agents for diseases against which activation of the thrombopoietin receptor.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Claims (14)

  1. Composé représenté par la formule (I) :
    Figure imgb0074
     dans laquelle
    A est un atome d'azote ou CR4 (où R4 est un atome d'hydrogène, un atome d'halogène ou un groupe alkyle en C1 à C6 (le groupe alkyle en C1 à C6 étant non substitué ou substitué par un ou plusieurs atome(s) d'halogène)), et quand A est un atome d'azote, B est NR5 (où R5 est un groupe alkyle en C1 à C6 (le groupe alkyle en C1 à C6 étant non substitué ou substitué par un ou plusieurs atome(s) d'halogène)), et quand A est CR4, B est un atome de soufre,
    L1 et L2 sont des liaisons simples,
    L3 est NR8 (où R8 est un atome d'hydrogène ou un groupe alkyle en C1 à C6 (le groupe alkyle en C1 à C6 étant non substitué ou substitué par un ou plusieurs atome(s) d'halogène)),
    L4 est une liaison simple ou NR13 (où R13 est un atome d'hydrogène ou un groupe alkyle en C1 à C6 (le groupe alkyle en C1 à C6 étant non substitué ou substitué par un ou plusieurs atome(s) d'halogène)),
    R1 est un groupe aryle en C2 à C14 condensé à un groupe cycloalcényle en C3 à C10, un groupe aryle en C2 à C14 condensé à un groupe hétérocyclyle en C2 à C9 ou un groupe aryle en C2 à C14 condensé à un groupe cycloalkyle en C3 à C10 (le groupe aryle en C2 à C14 condensé à un groupe cycloalcényle en C3 à C10, le groupe aryle en C2 à C14 condensé à un groupe hétérocyclyle en C2 à C9 et le groupe aryle en C2 à C14 condensé à un groupe cycloalkyle en C3 à C10 étant non substitués ou substitués par un ou plusieurs substituant(s) identique(s) ou différent(s) choisi(s) dans le jeu de substituants V1),
    R2 est un atome d'hydrogène ou un groupe alkyle en C1 à C6 (le groupe alkyle en C1 à C6 étant non substitué ou substitué par un ou plusieurs atome(s) d'halogène)),
    X est OH,
    Y est un atome d'oxygène ou un atome de soufre, et
    R3 est un groupe hétérocyclyle en C2 à C9 ou un groupe aryle en C2 à C14 (le groupe hétérocyclyle en C2 à C9 et le groupe aryle en C2 à C14 étant non substitués ou substitués par un ou plusieurs substituant(s) identique(s) ou différent(s) choisi(s) dans le jeu de substituants V1), et le jeu de substituants V1 est constitué par les groupes phosphono, les groupes sulfo, les groupes tétrazolyle, les groupes formyle, les groupes nitro, les groupes cyano, les atomes d'halogène, les groupes alkyle en C1 à C6, les groupes alcényle en C2 à C6, les groupes alcynyle en C2 à C6, les groupes aryle en C2 à C14, les groupes hétérocyclyle en C2 à C9 -(les groupes alkyle en C1 à C6, les groupes alcényle en C2 à C6, les groupes alcynyle en C2 à C6, les groupes aryle en C2 à C14 et les groupes hétérocyclyle en C2 à C9 étant non substitués ou substitués par un ou plusieurs substituant(s) identique(s) ou différent(s) choisi(s) parmi les groupes carboxy, les groupes carbamoyle, les groupes sulfamoyle, les groupes phosphono, les groupes sulfo, les groupes tétrazolyle, les groupes formyle, les groupes nitro, les groupes cyano, les atomes d'halogène, les groupes alkyle en C1 à C6, les groupes halogénoalkyle en C1 à C3, les groupes alcoxy en C1 à C6, les groupes halogénoalcoxy en C1 à C3, les groupes hydroxy, les groupes amino, les groupes monoalkylamino en C1 à C6, les groupes di (alkyle en C1 à C6) amino, les groupes mono(alkyle en C1 à C6)aminocarbonyle, les groupes di(alkyle en C1 à C6)aminocarbonyle, les groupes (alkyle en C1 à C6) carbonylamino, les groupes alkylthio en C1 à C6, les groupes alkylsulfonyle en C1 à C6, les groupes aryle en C2 à C14 et les groupes hétérocyclyle en C2 à C9 - (les groupes aryle en C2 à C14 et les groupes hétérocyclyle en C2 à C9 étant non substitués ou substitués par un ou plusieurs groupe(s) carboxy, un ou plusieurs groupe(s) carbamoyle, un ou plusieurs groupe(s) sulfamoyle, un ou plusieurs groupe(s) phosphono, un ou plusieurs groupe(s) sulfo, un ou plusieurs groupe(s) tétrazolyle, un ou plusieurs groupe(s) formyle, un ou plusieurs groupe(s) nitro, un ou plusieurs groupe(s) cyano, un ou plusieurs atome(s) d'halogène, un ou plusieurs groupe(s) alkyle en C1 à C6, un ou plusieurs groupe(s) halogénoalkyle en C1 à C6, un ou plusieurs groupe (s) alcoxy en C1 à C6, un ou plusieurs groupe(s) halogénoalcoxy en C1 à C6, un ou plusieurs groupe(s) hydroxy, un ou plusieurs groupe(s) amino, un ou plusieurs groupe(s) monoalkylamino en C1 à C6, un ou plusieurs groupe(s) di(alkyle en C1 à C6)amino, un ou plusieurs groupe(s) mono(alkyle en C1 à C6)aminocarbonyle -(les groupes mono(alkyle en C1 à C6)aminocarbonyle étant non substitués ou substitués par un ou plusieurs substituant(s) choisi(s) parmi les groupes hydroxy, les groupe(s) aryle en C2 à C14 et les groupes hétérocyclyle en C2 à C9), un ou plusieurs groupe(s) di(alkyle en C1 à C6)aminocarbonyle, un ou plusieurs groupe (s) (alkyle en C1 à C6)carbonylamino, un ou plusieurs groupe (s) alkylthio en C1 à C6 ou un ou plusieurs groupe(s) alkylsulfonyle en C1 à C6)) et les structures représentées par la formule (II) suivante :
    Figure imgb0075
     (où chacun de R17, R18 et R19 est indépendamment un atome d'hydrogène, un groupe alkyle en C1 à C6, un groupe alcényle en C2 à C6, un groupe alcynyle en C2 à C6, un groupe hétérocyclyle en C2 à C9 ou un groupe aryle en C2 à C14 (le groupe alkyle en C1 à C6, le groupe alcényle en C2 à C6, le groupe alcynyle en C2 à C6, le groupe hétérocyclyle en C2 à C9 et le groupe aryle en C2 à C14 étant non substitués ou substitués par un ou plusieurs substituant(s) identique(s) ou différent(s) choisi(s) parmi les groupes carboxy, les groupes carbamoyle, les groupes sulfamoyle, les groupes phosphono, les groupes sulfo, les groupes tétrazolyle, les groupes formyle, les groupes nitro, les groupes cyano, les atomes d'halogène, les groupes alkyle en C1 à C6, les groupes halogénoalkyle en C1 à C3, les groupes alcoxy en C1 à C6, les groupes halogénoalcoxy en C1 à C3, les groupes hydroxy, les groupes amino, les groupes monoalkylamino en C1 à C6, les groupes di(alkyle en C1 à C6)amino, les groupes mono(alkyle en C1 à C6)aminocarbonyle, les groupes di(alkyle en C1 à C6)aminocarbonyle, les groupes (alkyle en C1 à C6)carbonylamino, les groupes alkylthio en C1 à C6, les groupes alkylsulfonyle en C1 à C6, les groupes aryle en C2 à C14 et les groupes hétérocyclyle en C2 à C9 (les groupes aryle en C2 à C14 et les groupes hétérocyclyle en C2 à C9 étant non substitués ou substitués par un ou plusieurs groupe(s) carboxy, un ou plusieurs groupe(s) carbamoyle, un ou plusieurs groupe(s) sulfamoyle, un ou nitro, un ou plusieurs groupe(s) cyano, un ou plusieurs atome(s) d'halogène, un ou plusieurs groupe(s) alkyle en C1 à C6, un ou plusieurs groupe(s) halogénoalkyle en C1 à C3, un ou plusieurs groupe (s) alcoxy en C1 à C6, un ou plusieurs groupe(s) halogénoalcoxy en C1 à C3, un ou plusieurs groupe(s) hydroxy, un ou plusieurs groupe(s) amino, un ou plusieurs groupe(s) monoalkylamino en C1 à C6, un ou plusieurs groupe (s) di (alkyle en C1 à C6)amino, un ou plusieurs groupe(s) mono(alkyle en C1 à C6)aminocarbonyle (les groupes mono(alkyle en C1 à C6)aminocarbonyle étant non substitués ou substitués par un ou plusieurs substituant(s) choisi(s) parmi les groupes hydroxy, les groupes aryle en C2 à C14 et les groupes hétérocyclyle en C2 à C9), un ou plusieurs groupe(s) di(alkyle en C1 à C6)aminocarbonyle, un ou plusieurs groupe(s) (alkyle en C1 à C6)carbonylamino, un ou plusieurs groupe (s) alkylthio en C1 à C6 ou un ou plusieurs groupe(s) alkylsulfonyle en C1 à C6)), ou bien NR17R18 dans son entier représente un groupe hétérocyclyle azoté en C2 à C9 (le groupe hétérocyclyle azoté en C2 à C9 étant non substitué ou substitué par un ou plusieurs groupe(s) carboxy, un ou plusieurs groupe(s) carbamoyle, un ou plusieurs groupe(s) sulfamoyle, un ou plusieurs groupe(s) phosphono, un ou plusieurs groupe(s) sulfo, un ou plusieurs groupe(s) tétrazolyle, un ou plusieurs groupe(s) formyle, un ou plusieurs groupe(s) nitro, un ou plusieurs groupe(s) cyano, un ou plusieurs atome(s) d'halogène, un ou plusieurs groupe(s) alkyle en C1 à C6, un ou plusieurs groupe(s) halogénoalkyle en C1 à C3, un ou plusieurs groupe(s) alcoxy en C1 à C6, un ou plusieurs groupe(s) halogénoalcoxy en C1 à C3, un ou plusieurs groupe(s) hydroxy, un ou plusieurs groupe(s) amino, un ou plusieurs groupe (s) monoalkylamino en C1 à C6, un ou plusieurs groupe(s) di(alkyle en C1 à C6)amino, un ou plusieurs groupe(s) mono(alkyle en C1 à C6)aminocarbonyle (les groupes mono(alkyle en C1 à C6)aminocarbonyle étant non substitués ou substitués par un ou plusieurs substituant(s) choisi(s) parmi les groupes hydroxy, les groupes aryle en C2 à C14 et les groupes hétérocyclyle en C2 à C9), les groupe (s) di(alkyle en C1 à C6)aminocarbonyle, un ou plusieurs groupe(s) (alkyle en C1 à C6)carbonylamino, un ou plusieurs groupe(s) alkylthio en C1 à C6 ou un ou plusieurs groupe(s) alkylsulfonyle en C1 à C6)),
    un tautomère ou un sel pharmaceutiquement acceptable du composé, ou un solvate de celui-ci.
  2. Composé selon la revendication 1, dans lequel
    A est un atome d'azote ou CH, quand A est un atome d'azote, B est NR5 (où R5 est un groupe alkyle en C1 à C6), et quand A est CH, B est un atome de soufre,
    L3 est NH,
    L4 est une liaison simple ou NH,
    R1 est un groupe phényle condensé à un groupe hétérocyclyle en C2 à C9 ou un groupe phényle condensé à un groupe cycloalkyle en C3 à C10,
    R2 est un atome d'hydrogène ou un groupe alkyle en C1 à C6, Y est un atome d'oxygène ou un atome de soufre, et
    R3 est un groupe hétérocyclyle azoté en C4 à C5 ou un groupe aryle en C4 à C6 (le groupe hétérocyclyle azoté en C4 à C5 et le groupe aryle en C4 à C6 étant non substitués ou substitués par un ou deux substituant(s) identique(s) ou différent(s) choisi(s) dans l'ensemble constitué par les groupes carboxy, les groupes nitro, les atomes d'halogène, les groupes (alcoxy en C1 à C6)carbonyle et CONR14R15 (où chacun de R14 et R15 est indépendamment un atome d'hydrogène ou un groupe alkyle en C1 à C6 (le groupe alkyle en C1 à C6 étant non substitué ou substitué par un ou plusieurs groupe (s) aryle en C4 à C6), ou bien NR14R15 dans son entier représente un groupe hétérocyclyle azoté en C4 à C5),
    un tautomère ou un sel pharmaceutiquement acceptable du composé, ou un solvate de celui-ci.
  3. Composé selon la revendication 2, dans lequel
    L4 est une liaison simple, Y est un atome d'oxygène, et R3 est un groupe thiényle (le groupe thiényle portant un seul substituant choisi dans l'ensemble constitué par un groupe carboxy, un groupe (alcoxy en C1 à C6)carbonyle, un groupe di(alkyle en C1 à C6)aminocarbonyle, un groupe mono(alkyle en C1 à C6)aminocarbonyle (le groupe mono(alkyle en C1 à C6)aminocarbonyle étant substitué par un groupe pyridyle) et un groupe pyrrolidine-1-carbonyle) ou un groupe phényle (le groupe phényle étant substitué par un groupe carboxy ou un groupe (alcoxy en C1 à C6)carbonyle et pouvant être encore substitué par un groupe nitro),
    L4 est une liaison simple, Y est un atome de soufre, et R3 est un groupe pipéridinyle (le groupe pipéridinyle étant non substitué ou substitué par un groupe carboxy ou un groupe (alkyle en C1 à C6)carbonyle), ou
    L4 est NH, Y est un atome de soufre, et R3 est un groupe phényle (le groupe phényle étant un groupe carboxy ou un groupe (alcoxy en C1 à C6)carbonyle et pouvant être encore substitué par un atome d'halogène),
    un tautomère ou un sel pharmaceutiquement acceptable du composé, ou un solvate de celui-ci.
  4. Composé selon la revendication 1, dans lequel
    A est un atome d'azote ou CH, quand A est un atome d'azote, B est NR5 (où R5 est un groupe alkyle en C1 à C6), et quand A est CH, B est un atome de soufre,
    L3 est NH,
    L4 est une liaison simple ou NH,
    R2 est un atome d'hydrogène ou un groupe alkyle en C1 à C6, Y est un atome d'oxygène ou un atome de soufre, et
    R3 est un groupe aryle en C4 à C6 (le groupe aryle en C4 à C6 étant substitué par un ou deux substituant (s) identique(s) ou différent(s) choisi(s) dans l'ensemble constitué par les groupes tétrazolyle et CONR17R18 (où R17 est un atome d'hydrogène ou un groupe alkyle en C1 à C3 et R18 est un groupe alkyle en C1 à C6 (le groupe alkyle en C1 à C6 étant substitué par un groupe aryle en C4 à C6 (le groupe aryle en C4 à C6 étant substitué par un groupe mono(alkyle en C1 à C6)aminocarbonyle (le groupe mono(alkyle en C1 à C6)aminocarbonyle étant non substitué ou substitué par un groupe hydroxy)))) et pouvant être en outre substitué par un ou deux substituant(s) identique(s) ou différent(s) choisi(s) dans l'ensemble constitué par les atomes d'halogène et les groupes nitro),
    un tautomère ou un sel pharmaceutiquement acceptable du composé, ou un solvate de celui-ci.
  5. Composé selon la revendication 4, dans lequel L4 est une liaison simple, Y est un atome d'oxygène, et R3 est un groupe phényle (le groupe phényle étant substitué par un groupe tétrazolyle), ou bien L4 est NH, Y est un atome de soufre, et R3 est un groupe phényle (le groupe phényle étant substitué par un groupe tétrazolyle), un tautomère ou un sel pharmaceutiquement acceptable du composé, ou un solvate de celui-ci.
  6. Composé selon la revendication 4, dans lequel L4 est une liaison simple, Y est un atome d'oxygène, et R3 est un groupe thiényle (le groupe thiényle étant substitué par un groupe mono(alkyle en C1 à C6)aminocarbonyle (le groupe mono(alkyle en C1 à C6)aminocarbonyle étant substitué par un groupe phényle (le groupe phényle étant substitué par un groupe mono(alkyle en C1 à C6)aminocarbonyle (le groupe mono(alkyle en C1 à C6)aminocarbonyle étant substitué par un groupe hydroxy)))), un tautomère ou un sel pharmaceutiquement acceptable du composé, ou un solvate de celui-ci.
  7. Composé selon l'une quelconque des revendications 1 à 6, dans lequel R1 est un groupe phényle condensé à un groupe cycloalkyle en C4 à C7 ou un groupe phényle condensé à un groupe hétérocyclyle oxygéné en C3 à C5, un tautomère ou un sel pharmaceutiquement acceptable du composé, ou un solvate de celui-ci.
  8. Composé selon l'une quelconque des revendications 1 à 6, dans lequel R1 est un groupe indanyle, un groupe tétrahydronaphtyle ou un groupe 2,3-dihydrobenzofuranyle, un tautomère ou un sel pharmaceutiquement acceptable du composé, ou un solvate de celui-ci.
  9. Composé selon l'une quelconque des revendications 1 à 8, dans lequel A est un atome d'azote, et B est NR5 (où R5 est un groupe méthyle), un tautomère ou un sel pharmaceutiquement acceptable du composé, ou un solvate de celui-ci.
  10. Composé selon l'une quelconque des revendications 1 à 8, dans lequel A est CH, et B est un atome de soufre, un tautomère ou un sel pharmaceutiquement acceptable du composé, ou un solvate de celui-ci.
  11. Activateur de récepteur de thrombopoïétine contenant, à titre d'agent actif, le composé tel que défini dans l'une quelconque des revendications 1 à 10, un tautomère ou un sel pharmaceutiquement acceptable du composé, ou un solvate de celui-ci.
  12. Agent prophylactique, thérapeutique ou améliorateur pour des maladies contre lesquelles l'activation du récepteur de thrombopoïétine est efficace, qui contient, à titre d'agent actif, l'activateur de récepteur de thrombopoïétine selon la revendication 11.
  13. Agent augmentant les plaquettes contenant, à titre d'agent actif, l'activateur de récepteur de thrombopoïétine selon la revendication 11.
  14. Médicament contenant, à titre d'agent actif, le composé selon l'une quelconque des revendications 1 à 10, un tautomère ou un sel pharmaceutiquement acceptable du composé, ou un solvate de celui-ci.
EP10825062.2A 2009-10-23 2010-10-22 Composés hétérocycles fusionnés et activateur du récepteur de la thrombopoïétine Not-in-force EP2492262B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009244852 2009-10-23
JP2010181032 2010-08-12
PCT/JP2010/068754 WO2011049213A1 (fr) 2009-10-23 2010-10-22 Composés hétérocycles fusionnés et activateur du récepteur de la thrombopoïétine

Publications (3)

Publication Number Publication Date
EP2492262A1 EP2492262A1 (fr) 2012-08-29
EP2492262A4 EP2492262A4 (fr) 2013-03-20
EP2492262B1 true EP2492262B1 (fr) 2016-04-20

Family

ID=43900436

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10825062.2A Not-in-force EP2492262B1 (fr) 2009-10-23 2010-10-22 Composés hétérocycles fusionnés et activateur du récepteur de la thrombopoïétine

Country Status (5)

Country Link
US (1) US8889732B2 (fr)
EP (1) EP2492262B1 (fr)
JP (1) JP5704073B2 (fr)
TW (1) TW201127376A (fr)
WO (1) WO2011049213A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140227780A1 (en) * 2011-10-03 2014-08-14 Nissan Chemical Industries, Ltd. Method for producing megakaryocytes and/or platelets from pluripotent stem cells
JP7066979B2 (ja) * 2016-06-02 2022-05-16 東ソー株式会社 ジ置換ベンゼンを有するカルバゾール化合物及びその用途
CN107141202A (zh) * 2017-06-29 2017-09-08 白银龙铭化工科技有限公司 7‑溴‑3,4‑二氢‑1（2h）‑萘酮化合物的合成方法
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040189A1 (fr) 1995-06-07 1996-12-19 Glaxo Group Limited Peptides et composes se fixant a un recepteur
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
ES2303338T3 (es) 1995-06-07 2008-08-01 Glaxo Group Limited Peptidos y compuestos que se unen a un receptor de trombopoyetina.
JPH1072492A (ja) 1996-09-02 1998-03-17 Hokuriku Seiyaku Co Ltd ペプチド化合物
EP0839808A1 (fr) * 1996-10-29 1998-05-06 Novartis AG Dérivés de pyrazole, procédés pour leur préparation et leur application comme herbicides
EP1349613A4 (fr) * 2000-12-19 2005-09-21 Smithkline Beecham Corp Mimetiques de thrombopoietine
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
UA82695C2 (uk) * 2003-06-06 2008-05-12 Нисан Кемикал Индастриз, Лтд. Гетероароматичні сполуки як активатори рецептора тромбопоетину
CA2588979C (fr) * 2004-12-08 2013-01-22 Nissan Chemical Industries, Ltd. Composes heterocycliques a substitution de 3 ethylidenehydrazino utilises en tant qu'activateurs du recepteur de la thrombopoietine
RU2401259C2 (ru) 2004-12-14 2010-10-10 Ниссан Кемикал Индастриз, ЛТД Амидные соединения и активаторы рецептора тромбопоэтина
EP1904472A1 (fr) 2005-07-15 2008-04-02 Nissan Chemical Industries, Ltd. Composes thiophenes et activateurs du recepteur thrombopoietine
US7960425B2 (en) 2005-07-20 2011-06-14 Nissan Chemical Industries, Ltd. Pyrazole compounds and thrombopoietin receptor activators
JP5205967B2 (ja) 2005-11-07 2013-06-05 日産化学工業株式会社 ヒドラジド化合物及びトロンボポエチンレセプター活性化剤
JP5157900B2 (ja) 2006-06-07 2013-03-06 日産化学工業株式会社 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
CN101514179A (zh) 2008-02-21 2009-08-26 上海恒瑞医药有限公司 吲哚酮亚乙基肼羰基化合物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
EP2492262A1 (fr) 2012-08-29
US8889732B2 (en) 2014-11-18
JPWO2011049213A1 (ja) 2013-03-14
US20120209005A1 (en) 2012-08-16
EP2492262A4 (fr) 2013-03-20
WO2011049213A1 (fr) 2011-04-28
JP5704073B2 (ja) 2015-04-22
TW201127376A (en) 2011-08-16

Similar Documents

Publication Publication Date Title
US8318796B2 (en) Heterocyclic compounds and thrombopoietin receptor activators
KR101215207B1 (ko) 아미드 화합물 및 트롬보포이에틴 리셉터 활성화제
JP4985402B2 (ja) 複素環化合物及びトロンボポエチンレセプター活性化剤
JP5157900B2 (ja) 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
KR101350099B1 (ko) 하이드라지드 화합물 및 트롬보포이에틴 리셉터 활성화제
EP2492262B1 (fr) Composés hétérocycles fusionnés et activateur du récepteur de la thrombopoïétine
JPWO2006062249A1 (ja) 置換ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
JPWO2006062247A1 (ja) 置換複素環化合物及びトロンボポエチンレセプター活性化剤
RU2358970C2 (ru) 3-алкилиденгидразино-замещенные гетероарильные соединения в качестве активаторов рецептора тромбопоэтина

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120419

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130215

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 7/08 20060101ALI20130211BHEP

Ipc: C07D 231/18 20060101AFI20130211BHEP

Ipc: C07D 401/12 20060101ALI20130211BHEP

Ipc: A61P 43/00 20060101ALI20130211BHEP

Ipc: A61K 31/381 20060101ALI20130211BHEP

Ipc: A61K 31/41 20060101ALI20130211BHEP

Ipc: A61P 9/10 20060101ALI20130211BHEP

Ipc: A61K 31/4155 20060101ALI20130211BHEP

Ipc: C07D 409/12 20060101ALI20130211BHEP

Ipc: A61K 31/454 20060101ALI20130211BHEP

Ipc: C07D 409/14 20060101ALI20130211BHEP

Ipc: C07D 409/04 20060101ALI20130211BHEP

Ipc: A61K 31/4439 20060101ALI20130211BHEP

Ipc: A61K 31/415 20060101ALI20130211BHEP

Ipc: A61P 7/06 20060101ALI20130211BHEP

Ipc: C07D 333/32 20060101ALI20130211BHEP

17Q First examination report despatched

Effective date: 20150325

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20151030

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 792291

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010032663

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 792291

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160420

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20160420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160822

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160721

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010032663

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

26N No opposition filed

Effective date: 20170123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161022

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20170918

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161022

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20171018

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20171018

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20101022

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160420

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602010032663

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20181022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181022